Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The human T-cell lymphoma/leukemia viruses.

Bernard J Poiesz1, Michael J Poiesz, David Choi

  • 1Department of Medicine, Upstate Medical University, SUNY Syracuse, New York 13120, USA. poieszb@upstate.edu

Cancer Investigation
|May 15, 2003
PubMed
Summary

Human T-cell leukemia viruses (HTLV) cause malignancies and neurological disorders. While difficult to treat, new therapies and vaccines offer hope for prevention and control of HTLV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory bowel disease in the aging population.

Inflammatory bowel diseases·2026
Same author

Multi-task artificial intelligence annotation of echocardiographic images: a retrospective multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.

Crohn's & colitis 360·2026
Same author

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.

The American journal of gastroenterology·2026
Same author

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Digestive diseases and sciences·2026
Same author

Primer: Understanding Medicare for Advanced Therapies for Inflammatory Bowel Disease.

The American journal of gastroenterology·2026

Area of Science:

  • Retroviruses
  • Oncology
  • Immunology

Background:

  • Primate retroviruses, including Human T-cell leukemia viruses (HTLV), are oncogenic and pathogenic in humans.
  • HTLV-I and HTLV-II are linked to T-cell malignancies and neurological/rheumatic disorders.
  • The viral protein Tax and host factor adult T-cell lymphoma-derived factor are implicated in cell transformation.

Purpose of the Study:

  • To review the mechanisms of HTLV-induced pathogenesis.
  • To discuss current treatment challenges and novel therapeutic approaches.
  • To highlight future directions in HTLV prevention and control.

Main Methods:

  • Literature review of HTLV pathogenesis and associated diseases.
  • Analysis of viral mechanisms, including Tax protein function and host-cell interactions.
  • Examination of immune response in disease development and progression.

Main Results:

  • HTLV activates proto-oncogenes and inhibits tumor suppressor mechanisms, similar to DNA tumor viruses.
  • Effective cell-mediated immunity can prevent HTLV-associated malignancies.
  • HTLV-induced cancers have poor prognosis with conventional chemotherapy.

Conclusions:

  • HTLV infection poses significant health risks, including cancers and neurological disorders.
  • Novel therapeutic strategies are under investigation for HTLV-related diseases.
  • Improved screening, vaccines, and therapies are crucial for future HTLV prevention and management.

Related Experiment Videos